3rd ANNUAL EGFR RESISTERS RESEARCH SUMMIT

November 13, 2021 to November 15, 2021

To complete your submission:

  • Click the arrow to the right of Abstract Submission in the Course Progress table:

  • Click the Start button
  • Complete the required fields
    • To Upload an Abstract:
      • Click Choose File
      • Select the appropriate file from your desktop
      • Click Open
      • Click the Upload button – When the process is complete your document will appear as a link and a Remove button will appear
  • Click Submit

 

The goal of this 3rd Annual EGFR Resisters Research Summit is to continue to identify, cultivate, and prepare Young Investigators working on targeted lung cancer therapies for successful careers that help to advance the field of EGFRm NSCLC and improve outcomes for the more than 2,600 EGFR Resisters in over 75 countries and all patients impacted by this disease.

Topics of interest for the 2021 meeting include:

  • Biology, biomarkers, mutation subtypes and co-mutations
  • Adjuvant and neo-adjuvant approaches
  • Management of advanced disease including acquired resistance
  • Management of CNS metastases and LMD
  • Radiation approaches including consolidation and oligoprogression
  • Long term effects of therapy, quality of life and advocacy
  • Equity and disparities

 

Presented by the EGFR Resisters and Creative Educational Concepts, LLC.

                                               

Supported through an independent educational grant from AstraZeneca.

Target Audience

  • North American-based Junior Faculty and Fellows (MDs, and MD/PhDs) involved in research related to EGFR-mutated adenocarcinoma of the lungs. We encourage thoracic oncologists, surgeons, radiation oncologists, pathologists, and related lab-based and translational researchers to submit!.
    • Junior Faculty (Instructors or Assistant Professors)
    • Trainee (Must be enrolled in an ACGME-accredited fellowship program or PhD postdoctoral fellowship)
  • Candidates must be based in North America and training must be completed at a North American-based institution.
  • All work must be unpublished original research in an area related to EGFR-mutated adenocarcinoma of the lungs. If your research has been disrupted due to COVID-19, we will also accept a Career Statement highlighting your goals and trajectory as related to this area, previously published information, journal club presentation, or other like projects representing professional development.
  • Abstracts to be presented at future medical meetings are eligible for submission.

Learning Objectives

  • Examine the impact of scholarly activity and clinical research on continuing professional development in medicine.
  • Evaluate strengths and weaknesses of EGFRm NSCLC research presented by investigator peers.
  • Collaborate with other professions and specialties in the thoracic oncology space to provide an optimal continuum of care for patients with lung cancer.
  • Improve public speaking and presentation skills to effectively present research findings to the larger medical and scientific community.
  • Explore “what it takes” to become a lung cancer researcher by discussing career challenges such as grant writing, research funding, academic appointments, etc. with leading expert investigators.

Additional Information

AttachmentSize
PDF icon Call for Abstracts327.46 KB
Course summary
Course opens: 
08/18/2021
Course expires: 
11/15/2021
Event starts: 
11/13/2021 - 4:00pm
Event ends: 
11/15/2021 - 5:00pm
Rating: 
0

Abstract Policies and Procedures:

  • Only one abstract submission per Young Investigator will be accepted.
  • Abstracts must conform to the abstract preparation instructions. Those that do not may be rejected.
  • Only original work completed by the Young Investigator will be accepted.
  • All accepted abstracts will be published in an electronic program to be provided to all attendees. The publication of electronic handout materials will not preclude publication or presentation elsewhere.

Selection Process:

Submission deadline is Wednesday, September 22, 2021 at 11:59 PM ET

  • Expert Faculty Judges will review and score all submissions. Number of abstracts to be selected for presentation will depend on quantity and quality of abstracts received.
  • All presentations will be conducted via videoconferencing, should include a modest number of slides, and will consist of a formal presentation with Q&A period for a maximum of 15 total minutes.

Awards:

An awards ceremony will be held at the completion of the meeting, at which time the award winners will be announced. Grant payments will be made directly to the affiliated institution of each winning Young Investigator after the live program date.

Finalists:

The finalists (authors of accepted abstracts) must attend the meeting in it’s entirety and will be provided with the following in advance:

  • Full tech support for video conferencing with technical assessment of computer equipment, camera, audio, software.
  • One-on-one coaching to improve scientific presentation skills and ability to respond to challenges & questions.
  • Virtual care package with resources to improve camaraderie and effectiveness for the virtual meeting.

Instructions for Abstract Preparation and Submission:

Identification: Upon entering the abstract submission website, you will be required to submit the following information:

  • Full name, degree(s), credential(s)
  • Mailing address
  • Daytime telephone and e-mail
  • Current institution
  • Previous institution (where research was conducted, if applicable)
  • Submitting author and study type: (Clinician Scientist, Research Scientist, Clinical Fellow, or Postdoctoral Research Fellow)

Format: Abstracts should be uploaded as a Microsoft Word document with your last name in the document name.

Abstracts should consist of a brief title (bolded) descriptive of the research. Include first and last names and degrees of the authors. Underline the presenting author’s name and list the name and location of the institution where research was completed. Do not identify authors or institutions in the body of the abstract. Sans serif font (such as Arial or Helvetica) is preferred. Do not use font sizes smaller than 10 point.

Abstract text must be 1,000 words or less. Please make sure all figures are high resolution (at least 300 dpi). No more than a total of 4 figures and/or tables per submission are permitted. Please limit figures to 1 graph or image each (i.e., no multiple-part figures). Legends should be included with the abstract text and not as part of the figures (not included in the 1,000-word limit); figures should be embedded in the abstract file and not included as separate attachments.

Organize the body of the abstract in the following manner:
a) Disclosure of relevant financial relationships (not included in word count)
b) A sentence stating the purpose of the study
c) A brief statement of methods
d) A summary of results
e) A statement of conclusions reached.

Notification:
Abstract Receipt: An automatic notice confirming abstract submission, "Thank you, your submission has been received," will be provided upon completion of the online submission process.
Abstract Acceptance: Notification of abstract acceptance or rejection will be provided via e-mail by the end of September.

Questions can be directed to Rebecca Weaver at weaverr@ceconcepts.com.

Agenda:

DayKey Components/Activities: DayKey Components/Activities: Evening
Saturday
  • TBD
  • Welcome
  • Introductions

Sunday

  • Morning scientific presentations*
  • Small-group breakout sessions
  • Afternoon scientific presentations*
  • Keynote Welcome Address

Monday

  • Morning scientific presentations*
  • Small-group breakout sessions
  • Afternoon scientific presentations*
  • Awards Presentation

 

Lecia V. Sequist, MD, MPH
Activity Chair
Landry Family Professor of Medicine
Harvard Medical School
Director of Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts

 



Christine M. Lovly, MD, PhD
Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Program
Section Chief, Basic and Translational Research
Vanderbilt University Medical Center
Vanderbilt Ingram Cancer Center
Nashville, Tennessee


Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

 

 

 



Helena Yu, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

 

 

 

 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Please login or register to take this course.